English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03233347 /

LY-1601

A Phase II Trial Of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, And Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With Or Without Brentuximab Vedotin Plus Nivolumab, Followed By Nivolumab Consolidation For Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: